| Literature DB >> 34945740 |
Asan Agibetov1, Andreas Kammerlander2, Franz Duca2, Christian Nitsche2, Matthias Koschutnik2, Carolina Donà2, Theresa-Marie Dachs2, René Rettl2, Alessa Stria1, Lore Schrutka2, Christina Binder2, Johannes Kastner2, Hermine Agis3, Renate Kain4, Michaela Auer-Grumbach5, Matthias Samwald1, Christian Hengstenberg2, Georg Dorffner1, Julia Mascherbauer2, Diana Bonderman2.
Abstract
AIMS: We tested the hypothesis that artificial intelligence (AI)-powered algorithms applied to cardiac magnetic resonance (CMR) images could be able to detect the potential patterns of cardiac amyloidosis (CA). Readers in CMR centers with a low volume of referrals for the detection of myocardial storage diseases or a low volume of CMRs, in general, may overlook CA. In light of the growing prevalence of the disease and emerging therapeutic options, there is an urgent need to avoid misdiagnoses. METHODS ANDEntities:
Keywords: artificial intelligence; cardiac amyloidosis; diagnostic ability; heart failure
Year: 2021 PMID: 34945740 PMCID: PMC8705947 DOI: 10.3390/jpm11121268
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Baseline characteristics of the study population.
| Non-Amyloidosis | Amyloidosis | ||
|---|---|---|---|
| Clinical parameters, median (IQR) | |||
| Age, years | 66.0 (50.0–75.0) | 75.0 (68.0–82.5) |
|
| Male sex, no. (%) | 188 (44.9) | 52 (65.8) |
|
| Height, cm | 169.5 (162.0–178.0) | 167.0 (162.5–172.0) | 0.578 |
| Weight, kg | 76.0 (65.8–88.2) | 75.0 (65.0–79.5) | 0.596 |
| Body mass index, kg/m2 | 27.0 (23.9–31.0) | 25.5 (23.9–28.7) | 0.066 |
| Laboratory parameters, median (IQR) | |||
| NT-proBNP, pg/mL | 452.0 (143.9–1380.0) | 3002.0 (1282.5–7453.0) |
|
| Serum creatinine, mg/dL | 0.9 (0.8–1.1) | 1.2 (1.0–1.6) |
|
| Estimated GFR, mL/min/1.73 m2 | 78.0 (55.0–106.0) | 50.0 (38.8–60.5) |
|
| C-Reactive Protein, mg/dL | 0.3 (0.1–0.7) | 0.3 (0.2–0.7) | 0.340 |
| Troponin T, mg/L | 17.0 (7.0–29.0) | 79.0 (64.0–122.0) |
|
| NYHA functional class, no. (%) |
| ||
| I | 167 (40.3) | 10 (12.8) | |
| II | 125 (30.2) | 24 (30.8) | |
| III | 107 (25.8) | 40 (51.3) | |
| IV | 13 (3.1) | 2 (2.6) | |
| Missing data | 2 (0.5) | 2 (2.6) | |
| Medical history, no. (%) | |||
| Hypertension | 304 (72.7) | 50 (63.3) | 0.236 |
| Atrial fibrillation | 127 (30.8) | 36 (46.2) | 0.031 |
| Coronary artery disease | 110 (26.6) | 20 (25.3) | 0.917 |
| Myocardial infarction | 42 (10.2) | 4 (5.1) | 0.339 |
| Percutaneous coronary intervention | 57 (13.7) | 8 (10.1) | 0.591 |
| Coronary artery bypass grafting | 22 (5.3) | 5 (6.3) | 0.829 |
| Diabetes mellitus type II | 77 (18.4) | 13 (16.5) | 0.829 |
| Treatment, no. (%) * | |||
| Oral anticoagulants | 134 (32.4) | 41 (52.6) |
|
| Diuretic agent | 153 (37.0) | 50 (64.1) |
|
| Mineralocorticoid-receptor antagonist | 99 (24.0) | 28 (35.9) | 0.084 |
| ACE inhibitor or ARB | 229 (55.4) | 36 (46.2) | 0.278 |
| Beta-blocker | 232 (56.2) | 36 (46.2) | 0.245 |
| Calcium channel antagonist | 66 (16.0) | 8 (10.3) | 0.478 |
| Statin | 159 (38.4) | 23 (29.5) | 0.278 |
| Cardiac magnetic resonance imaging parameters, median (IQR) | |||
| Myocardial native T1 time, ms | 1050.9 (998.1–1103.8) | 1107.6 (1074.5–1140.7) |
|
| Extracellular volume, % | 33.5 (28.8–38.3) | 46.7 (40.6–52.8) |
|
* Medication at the time point of referral to expert center. Values are given as median and interquartile range (IQR) or total numbers and percent. Bold numbers indicate statistical significance with p-values < 0.05. HF indicates heart failure; NT-proBNP, n- terminal prohormone of brain natriuretic peptide; GFR, glomerular filtration rate; NYHA, New York Heart Association; ACE, angiotensin converting enzyme; and ARB, angiotensin receptor blocker.
Ten-fold cross-validated performance of prediction models for different imaging protocols.
| Imaging Protocol | Feature Extraction | From Scratch | Fine-Tuning | ||||
|---|---|---|---|---|---|---|---|
| ROC AUC | Se (Sp) | ROC AUC | Se (Sp) | ROC AUC | Se (Sp) | ||
| LGE | Patient | 0.96 | 0.97 (0.81) | 0.95 | 0.91 (0.91) | 0.96 | 0.94 (0.9) |
| Image | 0.87 | 0.8 (0.77) | 0.89 | 0.82 (0.81) | 0.93 | 0.82 (0.88) | |
| MOLLI | Patient | 0.92 | 0.85 (0.86) | 0.92 | 0.86 (0.86) | 0.93 | 0.91 (0.82) |
| Image | 0.84 | 0.72 (0.8) | 0.88 | 0.79 (0.82) | 0.91 | 0.8 (0.87) | |
| CINE | Patient | 0.91 | 0.77 (0.95) | 0.89 | 0.84 (0.82) | 0.90 | 0.85 (0.86) |
| Image | 0.81 | 0.69 (0.78) | 0.84 | 0.72 (0.83) | 0.88 | 0.78 (0.85) | |
Note: LGE—late gadolinium enhancement, MOLLI—modified look-locker inversion recovery, Patient—average prediction over all images of a patient, and Image—prediction on one image. ROC AUC scores are averages of 10-fold cross-validation. Sensitivity and specificity are computed from mean receiver operating curves with Youden’s J statistic. The best results are in bold. ROC AUC-Area under Receiver Operating Characteristic Curve, Se-Sensitivity, Sp–Specificity.
Figure 1Image (panels (A–C)) and patient (panels (D–F)) classification performance by LGE images for all models measured with ROC curves. ROC AUC—Area under Receiver Operating Characteristic Curve, Sens.—Sensitivity, Spec.—Specificity.
Figure 2Image (panels (A–C)) and patient (panels (D–F)) classification performance by MOLLI images for all models measured with ROC curves. ROC AUC—Area under Receiver Operating Characteristic Curve, Sens.—Sensitivity, Spec.—Specificity.
Figure 3Image (panels (A–C)) and patient (panels (D–F)) classification performance by CINE images for all models measured with ROC curves. ROC AUC—Area under Receiver Operating Characteristic Curve, Sens.—Sensitivity, Spec.—Specificity.